Skip to main content
. Author manuscript; available in PMC: 2015 Mar 11.
Published in final edited form as: N Engl J Med. 2014 Sep 3;371(11):1028–1038. doi: 10.1056/NEJMoa1315815

Figure 1. Transcript Levels of Full-Length Androgen Receptor mRNA and AR-V7 in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer.

Figure 1

Absolute transcript copy numbers of full-length androgen receptor messenger RNA (mRNA) and androgen-receptor splice variant 7 mRNA (AR-V7) detected in circulating tumor cells are shown for the 6 abiraterone-treated patients (Panel A) and the 12 enzalutamide-treated patients (Panel B) who were positive for AR-V7 at baseline (i.e., in pretreatment samples of circulating tumor cells). Ratios of AR-V7 to full-length androgen receptor mRNA are expressed as percentages. Levels of full-length androgen receptor mRNA are also shown for AR-V7–negative samples. Eight abiraterone-treated patients who were negative for full-length androgen receptor mRNA (not shown) were also negative for AR-V7. One enzalutamide-treated patient was negative for both full-length androgen receptor mRNA and AR-V7 (not shown).